These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 29274141)

  • 1. Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.
    Wang YT; Yuan B; Chen HD; Xu L; Tian YN; Zhang A; He JX; Miao ZH
    Cancer Sci; 2018 Mar; 109(3):821-831. PubMed ID: 29274141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
    Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
    Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
    Fedier A; Maggi N; Tozzi A; Disler M; Coelho R; Jacob F; Heinzelmann-Schwarz V
    Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35642662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
    BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma.
    Zhang X; Huang P; Wang L; Chen S; Basappa B; Zhu T; Lobie PE; Pandey V
    Cell Death Dis; 2022 Jun; 13(6):558. PubMed ID: 35725817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C.
    Giansanti M; De Gabrieli A; Prete SP; Ottone T; Divona MD; Karimi T; Ciccarone F; Voso MT; Graziani G; Faraoni I
    J Pharmacol Exp Ther; 2021 Jun; 377(3):385-397. PubMed ID: 33820831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
    Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
    Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH
    Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
    PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
    Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
    Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
    Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
    Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
    [No Abstract]   [Full Text] [Related]  

  • 15. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
    Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
    J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
    Li J; Wang R; Kong Y; Broman MM; Carlock C; Chen L; Li Z; Farah E; Ratliff TL; Liu X
    Mol Cancer Ther; 2017 Mar; 16(3):469-479. PubMed ID: 28069876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
    Miyasaka A; Oda K; Ikeda Y; Wada-Hiraike O; Kashiyama T; Enomoto A; Hosoya N; Koso T; Fukuda T; Inaba K; Sone K; Uehara Y; Kurikawa R; Nagasaka K; Matsumoto Y; Arimoto T; Nakagawa S; Kuramoto H; Miyagawa K; Yano T; Kawana K; Osuga Y; Fujii T
    BMC Cancer; 2014 Mar; 14():179. PubMed ID: 24625059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
    Jaspers JE; Kersbergen A; Boon U; Sol W; van Deemter L; Zander SA; Drost R; Wientjens E; Ji J; Aly A; Doroshow JH; Cranston A; Martin NM; Lau A; O'Connor MJ; Ganesan S; Borst P; Jonkers J; Rottenberg S
    Cancer Discov; 2013 Jan; 3(1):68-81. PubMed ID: 23103855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.